Vantaa, Finland – May 8th 2025 – Kohde Pharma Oy, a newly incorporated pharmaceutical company in Finland, is pleased to announce that it has secured its first investment from Finnish Drug Discovery Center Ltd (FDDC). This investment will support the initial development of Kohde Pharma’s proprietary asset, which targets the unmet clinical need in MTAP deleted tumors through a novel target mechanism.
“We are thrilled to receive this investment from FDDC, which will enable us to advance our innovative and targeted approach to treating MTAP deleted tumors,” said Thomas Wirth, CEO of Kohde Pharma. “With FDDC’s scientific support, we are confident in our ability to make significant strides in addressing this critical need.”
Kohde Pharma’s asset represents a promising new direction in cancer treatment, driving clinical success by leveraging AI and patient derived intelligence to uncover novel therapeutic targets with the potential to transform outcomes for patients with MTAP deleted tumors who currently have limited treatment options. MTAP deletion is a very common alteration comprising between 10-15% of human cancers.
“We are excited about this new biotech company in Finland and our ability to sup-port their mission to develop innovative treatments for MTAP deleted tumors,” said Maarit Merla, CEO of FDDC. “Our pre-seed investment and scientific support will help accelerate the development of this promising asset, potentially transforming the landscape of cancer treatment. We look forward to our journey together with Kohde Pharma.”
FDDC is a state-owned company with a special assignment to promote competitive drug development and commercial success of Finland in this sector. The company mission is to become a valued partner of the research community in turning innovative drug compounds into international success stories. FDDC’s commitment to advancing scientific research and supporting innovative companies like Kohde Pharma underscores its dedication to improving patient outcomes and addressing critical healthcare needs.
For more information, please contact:
• Thomas Wirth, CEO of Kohde Pharma: thomas@kohde.bio
• Maarit Merla, CEO of Finnish Drug Discovery Center: maarit.merla@ddcenter.fi